Dual antiplatelet therapy in patients with acute coronary syndrome treated by surgical revascularization
| Authors | |
|---|---|
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Cor et Vasa |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1016/j.crvasa.2014.04.005 |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | ACS; CABG; Clopidogrel; Dual antiplatelet therapy; Surgery revascularization; Ticagrelor |
| Description | Twelve months dual antiplatelet therapy (DAPT) based on a combination of acetylsalicylic acid and purine receptor P2Y12 inhibitor is a standard for all patients with acute coronary syndrome (unstable angina pectoris, NSTEMI and STEMI). Previous sub-analysis of CURE and ACUITY studies suggested that DAPT could bring benefit even for patients treated by surgical revascularization. Sub-analysis of PLATO trial conducted on 1261 patients, who underwent surgical revascularization within 12 months, demonstrated a reduction of cardiovascular and total mortality within a group of patients treated by ticagrelor and acetylsalicylic acid compared to patients treated by clopidogrel and acetylsalicylic acid. |